Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Innate Pharma    IPH   FR0010331421

INNATE PHARMA

(IPH)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Summary
  • The company usually posts poor financials for mid or long term investments.
Strengths
  • The current area is a good opportunity for investors interested in buying the stock in a mid or long-term perspective. Indeed, the share is moving closer to its lower bound at EUR 3.07 EUR in weekly data.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Historically, the company has been releasing figures that are above expectations.
  • For the past twelve months, EPS forecast has been revised upwards.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
  • According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
  • The company has insufficient levels of profitability.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
  • Revenue estimates are regularly revised downwards for the current and coming years.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • For the past year, analysts have significantly revised downwards their profit estimates.
Ratings chart
Sector Biotechnology & Medical Research - NEC
1st jan.Capitalisation (M$)Investor Rating
INNATE PHARMA10.75%366
MODERNA, INC.24.10%51 304
LONZA GROUP AG3.27%49 041
CELLTRION, INC.-8.36%40 715
IQVIA HOLDINGS INC.4.81%36 004
SEAGEN INC.6.06%33 601
HANGZHOU TIGERMED CONSULTIN..0.37%21 655
INCYTE CORPORATION5.82%19 832
ALNYLAM PHARMACEUTICALS, IN..28.00%19 328
PHARMARON BEIJING CO., LTD.3.82%15 119
CRISPR THERAPEUTICS AG30.55%14 233
CHARLES RIVER LABORATORIES ..9.55%13 616
BIO-TECHNE CORPORATION9.50%13 425
PPD, INC.6.66%12 762
QIAGEN N.V.0.66%12 098
ICON PUBLIC LIMITED COMPANY7.88%11 101
More Results
Financials
Sales 2020 85,7 M 103 M 103 M
Net income 2020 -30,8 M -37,2 M -37,2 M
Net cash 2020 152 M 183 M 183 M
P/E ratio 2020 -5,47x
Yield 2020 -
Capitalization 303 M 366 M 366 M
EV / Sales 2020 1,76x
EV / Sales 2021 4,00x
Nbr of Employees 247
Free-Float 75,3%
Upcoming event on INNATE PHARMA
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating
Investor Rating
Growth (Revenue)
Valuation
Finances
Profitability
Earnings quality
Business Predictability
P/E ratio -
Potential
Yield -
Consensus
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision
Technical ratings
Short Term Timing
Middle Term Timing
Long Term Timing
RSI
Bollinger Spread
Unusual Volumes